September 28, 2021
2 min watch
Save
VIDEO: Neoadjuvant immunotherapy ‘shows a lot of promise’ in early-stage NSCLC
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Healio spoke with Jae Y. Kim, MD, about a study presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.
The trial investigated neoadjuvant pembrolizumab in early-stage non-small cell lung cancer.
“It’s an exciting area of research for patients who are in early-stage disease,” Kim, chief of thoracic surgery and associate professor at City of Hope, said.
Reference:
- Bar J, et al. Abstract OA11.01. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (virtual meeting); Sept. 8-14, 2021.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Kim reports receiving a research grant to his institution from Eli Lily and serving as a consultant for AstraZeneca.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.